The estimated Net Worth of Srinivas Akkaraju is at least $8.2 Million dollars as of 1 June 2024. Srinivas Akkaraju owns over 4,000 units of Intercept Pharmaceuticals Inc stock worth over $126,654 and over the last 20 years he sold ICPT stock worth over $7,760,432. In addition, he makes $316,356 as Independent Director at Intercept Pharmaceuticals Inc.
Srinivas has made over 32 trades of the Intercept Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of ICPT stock worth $76,000 on 1 June 2024.
The largest trade he's ever made was buying 2,189,781 units of Intercept Pharmaceuticals Inc stock on 16 October 2023 worth over $15,000,000. On average, Srinivas trades about 78,074 units every 38 days since 2004. As of 1 June 2024 he still owns at least 6,666 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Srinivas Akkaraju stock trades at the bottom of the page.
Dr. Srinivas Akkaraju M.D. Ph.D. serves as Independent Director of the Company. Since March 2017, Dr. Akkaraju has been the Managing General Partner of Samsara BioCapital, a venture capital firm that he founded. From April 2013 to March 2017, Dr. Akkaraju was a General Partner and then a Senior Advisor of Sofinnova Ventures, a venture capital firm focused on the life sciences industry. From January 2009 until April 2013, Dr. Akkaraju was a Managing Director of New Leaf Venture Partners, an investment firm focused on the healthcare technology sector. From 2006 to 2008, Dr. Akkaraju served as a Managing Director of Panorama Capital, a venture capital firm that he co-founded along with other members of the former venture capital investment team of J.P. Morgan Partners, a private equity division of JPMorgan Chase & Co. Prior to co-founding Panorama Capital, Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a partner in 2005. From 1998 to 2001, Dr. Akkaraju worked in business and corporate development at Genentech, Inc. (now a member of the Roche Group), a biotechnology company. Dr. Akkaraju has been a director of Seattle Genetics, Inc. since 2003, Aravive, Inc. (formerly Versartis, Inc.) since July 2013 and Syros Pharmaceuticals, Inc. since June 2017. Dr. Akkaraju also serves on the board of directors of a number of private companies. During the prior five years, Dr. Akkaraju previously served as a director of aTyr Pharma, Inc., Principia Biopharma Inc. and ZS Pharma, Inc. Dr. Akkaraju received his M.D. and a Ph.D. in Immunology from Stanford University. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University.
As the Independent Director of Intercept Pharmaceuticals Inc, the total compensation of Srinivas Akkaraju at Intercept Pharmaceuticals Inc is $316,356. There are 17 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.
Srinivas Akkaraju is 52, he's been the Independent Director of Intercept Pharmaceuticals Inc since 2012. There are 11 older and 9 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Srinivas's mailing address filed with the SEC is 301 BINNEY STREET, , CAMBRIDGE, MA, 02142.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: